The earnings call reflects a generally positive sentiment with strong sales growth, successful new product launches, and strategic acquisitions enhancing Sanofi's position in key markets. However, challenges in flu vaccine sales and mixed clinical trial results present areas of concern.

Company Guidance -

Q3 2025

During the Q2 2025 Sanofi conference call, the company provided detailed guidance on its performance and expectations for the remainder of the year. Sanofi reported a 10.1% increase in net sales at constant exchange rates for Q2, driven by a strong performance in immunology, pharmaceutical launches, and Beyfortus, with Dupixent sales reaching EUR 3.8 billion, marking a 21% increase. The company adjusted its 2025 sales guidance to high single-digit percentage growth at constant exchange rates, citing confidence in continued top-line performance from new launches and vaccines. Sanofi also highlighted the completion of its Blueprint Medicines acquisition, which, although not included in Q2 financials, is expected to strengthen its rare immunology disease portfolio. The CFO, François-Xavier Roger, noted an improvement in gross margin by 1.5 percentage points and increased R&D expenses by 17.7%, driven by strategic investments despite a lower base of comparison from the previous year. For the full year 2025, Sanofi anticipates high single-digit sales growth and confirmed its EPS guidance of low double-digit growth at constant exchange rates. The company remains focused on its long-term strategic goals, with expectations of maintaining an attractive growth profile and tight control on costs.

Strong Double-Digit Sales Growth

Sanofi delivered strong performance in Q2 2025 with a 10.1% increase in net sales at constant exchange rates, driven by Immunology, pharma launches, and Beyfortus.

Dupixent Sales Surge

Dupixent sales reached EUR 3.8 billion, up 21% in Q2, driven by continued strong demand and improved indications across geographies.

Vaccine Business Growth

Vaccine sales increased by 10.3% in Q2, driven by Beyfortus expansion and benefiting from the effect of the late 2024-2025 flu season in the Northern Hemisphere.

Successful Launch of New Products

New launches generated close to EUR 1 billion in sales in Q2, maintaining momentum from Q1. These launches now represent 10% of Sanofi's total sales.

Strategic Acquisitions

Sanofi completed the acquisition of Blueprint Medicines, significantly strengthening its position in rare immunology diseases, particularly with Ayvakit in systemic mastocytosis.

Commitment to Sustainability

Sanofi was ranked as the world's 10th most sustainable company by TIME and #1 in pharma and biotech. The company is incorporating eco-design principles into all new medicines and vaccines by 2025.

Sanofi (SNY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SNY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2025 (Q3)	1.63 / -	1.549	―	―	―
Jul 31, 2025	2025 (Q2)	0.96 / 0.91	0.939	-3.09% (-0.03)
Apr 24, 2025	2025 (Q1)	0.93 / 0.79	0.953	-17.63% (-0.17)
Jan 30, 2025	2024 (Q4)	0.70 / 0.68	0.899	-24.03% (-0.22)
Oct 25, 2024	2024 (Q3)	1.35 / 1.55	1.349	14.83% (+0.20)
Jul 25, 2024	2024 (Q2)	0.89 / 0.94	0.96	-2.19% (-0.02)
Apr 25, 2024	2024 (Q1)	0.93 / 0.95	1.189	-19.85% (-0.24)
Feb 01, 2024	2023 (Q4)	0.94 / 0.90	0.928	-3.13% (-0.03)
Oct 27, 2023	2023 (Q3)	1.37 / 1.35	1.433	-5.86% (-0.08)
Jul 28, 2023	2023 (Q2)	0.93 / 0.96	0.878	9.34% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SNY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$49.25	$45.64	-7.33%
Apr 24, 2025	$51.38	$51.89	+0.99%
Jan 30, 2025	$50.54	$52.48	+3.84%
Oct 25, 2024	$50.44	$52.66	+4.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.